Investors Alert: Important Class Action Lawsuit for Capricor Therapeutics, Inc. Shareholders

Important Alert for Capricor Investors

On August 27, 2026, SueWallSt notified shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) about a significant securities class action. This impending lawsuit aims to hold the company's leadership accountable for alleged misstatements and nondisclosure concerning the HOPE-3 trial's pre-specified statistical analysis.

The situation stems from claims that Capricor's CEO, Linda Marbán, and CFO, Anthony J. Bergmann, certified misleading public statements while allegedly controlling and overseeing the company's communications regarding the trial. These statements reportedly omitted crucial changes made to the study's statistical analysis plan that were not agreed upon with the FDA, leading to investor confusion and financial losses.

The Decline in Stock Price

Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, should be particularly concerned. The company’s stock plummeted from $19.70 per share on July 24, 2026, to just $4.19, marking a steep decline of about 78.7%. This significant drop reflected a loss of approximately $15.08 per share tied to corrective disclosures revealing the unapproved changes to the statistical analysis plan.

Actions for Affected Investors

To qualify as a lead plaintiff in this ongoing class action, affected investors must file by September 28, 2026. Interested parties can evaluate their eligibility for potential compensation by contacting attorney Joseph E. Levi at SueWallSt, who specializes in securities litigation. Legal representatives emphasize that investors simply require documentation of their brokerage transactions during the specified class period.

Allegations Against Individual Defendants

The allegations against Marbán and Bergmann assert that both had direct oversight of and authority over Capricor's reports and public communications. Each defendant is thought to have received relevant statements before they were published, with the ability to correct any inaccuracies. Furthermore, neither individual disclosed that the changes to the statistical analysis plan had not been approved by the FDA before the resubmission of the Biologics License Application.

Liability Under Securities Laws

The lawsuit's basis lies in Section 20(a) of the Securities Exchange Act of 1934, which allows recovery from individuals who may be deemed as controlling violators. Therefore, Capricor's senior executives could potentially face personal liability for their role in disseminating misleading information to investors.

Importance of Timely Action

Investors are advised that no upfront costs are associated with participating in this class action, as it operates on a contingency basis. Therefore, it’s crucial for affected shareholders to gather all relevant purchase records, including dates, share quantities, and prices paid, to increase the likelihood of compensation.

The urgency of filing to protect investors’ interests cannot be overstated. A proactive approach in gathering necessary documentation and seeking legal advice will help ensure impacted shareholders are not left without recourse due to the recent upheaval surrounding Capricor's reporting practices.

Conclusion

In summary, Capricor Therapeutics, Inc. shareholders have an important opportunity to participate in a class action lawsuit that may offer financial restitution for losses incurred during the disputed timeframe. For those negatively impacted by the steep decline in stock value, immediate attention to the details of this case may prove critical. It’s essential to stay informed and to act decisively to safeguard your investments.

For further information or to inquire about potential eligibility, investors are encouraged to reach out directly to the legal representatives at SueWallSt.